http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016228410-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_114e4423ec77cbc8dab9d0a98909704e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b53866dce529b32939fa8738f1b5279c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 |
| filingDate | 2014-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a739c93ec1daaee1ed7c2ef40b971ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f74cab924ac72d1ce2ca40f7609eb567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e8c702eb3d6ffaa9955bf5ab6e58993 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1834fb7fa0c428c23c7ec1b340f1685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13f8f0387095e7595b47349540aa7cac |
| publicationDate | 2016-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2016228410-A1 |
| titleOfInvention | An anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells |
| abstract | The present invention provides the compound Ormeloxifene [3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy)phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like C/EBPα and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (GCSFr). Differentiated cells having neutrophil like morphology were observed when treated with 1.0 uM to 7.5 uM ORM which clearly indicates that ORM can induce differentiation in myeloid leukemia cells. At higher doses (5 uM to 7.5 uM) there is early onset of myeloid differentiation (24 to 48 h) with reduced no. of cells which is likely due to apoptotic effects of ORM at higher does. In contrary, lower doses (1 uM) induce differentiation after longer duration (6-15 days) with quite reduced apoptotic effect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110585197-A |
| priorityDate | 2013-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 131.